Respiratory Syncytial Virus (RSV) Luminescent Reporter Strain
Application
Modified respiratory syncytial virus (RSV) expressing a bioluminescent reporter protein for high throughput screening, vaccine development, and drug discovery. Plasmid encoding virus also available.
Key Benefits
- Provides a new high throughput screening tool for RSV vaccine development and drug discovery.
- Bioluminescent assays outperform fluorescent assays for high throughput screening purposes, with better sensitivity, broad linearity, and robustness to compounds and biological samples.
- Renilla luciferase is compatible with live cell measurements.
Market Summary
RSV is a major cause of respiratory illness in infants, young children, and in recent years, the elderly. Currently there is no effective vaccine or small molecule drug against RSV, therefore there is a distinct need for tools and strategies to enable RSV vaccine development and drug discovery.
Technical Summary
Emory researchers, Drs. Moore and Plemper, have created a recombinant RSV strain that expresses Renilla luciferase in the first gene position of the RSV genome. Renilla luciferase is a bioluminescent protein originally derived from sea pansies that has been widely used as a genetic reporter in high throughput screening assays. In this modified RSV, the bioluminescence serves as a reporter for RSV infection or replication activity. Because of this reporter activity, this RSV strain serves as an excellent tool for the high throughput screening of antiviral agents (drug development) and measurement anti-RSV antibodies (vaccine studies).
Developmental Stage
The bioluminescent RSV strain has been successfully engineered and is available to distribute.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
|
|
